We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Perrigo Company plc (PRGO - Free Report) reported adjusted earnings of 93 cents per share in the fourth quarter of 2024, beating the Zacks Consensus Estimate of 92 cents. The reported figure increased 8% year over year, primarily due to improved margins and lower variable expenses.
Net sales declined 1.6% year over year to $1.14 billion, missing the Zacks Consensus Estimate of $1.20 billion. The downside was due to the loss of sales stemming from exited businesses and product lines.
During the quarter, sales dropped 2.1% year over year on account of exited businesses and product lines and another 0.1% from unfavorable currency movement. At constant currency (excluding foreign currency translation), sales fell 1.5%. Organic net sales (excluding the effects of acquisitions and divestitures and the impact of currency) rose 0.7%.
Year to date, shares of Perrigo have lost 6.1% against the industry’s 11% growth.
Image Source: Zacks Investment Research
More on PRGO’s Earnings
Perrigo reports its results under the following segments — Consumer Self Care Americas (CSCA) and Consumer Self Care International (CSCI).
CSCA: The segment’s net sales in the quarter came in at $744 million, flat year over year. Though sales grew across the Nutrition, Skin Care and Women's Health categories, sales in the Pain & Sleep Aids, Upper Respiratory and Digestive Health categories offset this growth. Organic net sales rose 0.1%.
CSCI: The segment reported net sales of $394 million, down 4.5% from the year-ago period’s levels due to product line exits and unfavorable currency movements. At constant currency rates, sales were down 4.1% year over year. Organically, sales increased 1.8%.
Full-Year 2024 Results
Perrigo reported revenues of $4.37 billion, down 6.1% year over year. Net sales also fell 4.5% organically.
The company reported adjusted earnings of $2.57 per share for 2024, down 0.4% year over year.
PRGO’s 2025 Guidance
Perrigo will be hosting a virtual Investor Day today, where management will share the company’s 2025-2027 strategic plan to boost performance. During the event, management will also issue its financial guidance for the full year 2025.
Estimates for argenx’s 2025 earnings per share (EPS) have increased from $2.07 to $3.13 over the past 60 days, while the same for 2026 has increased from $9.08 to $10.85. ARGX’s shares have gained 2% year to date.
argenx's earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 339.37%.
Estimates for Pacira BioSciences’ 2025 EPS have increased from $3.16 to $3.20 over the past 60 days, and the same for 2026 has risen from $2.79 to $3.59. PCRX’s shares have surged 35% year to date.
Pacira’s earnings beat estimates in two of the trailing four quarters, missed once and met in the other, delivering an average surprise of 7.13%.
Estimates for 89bio’s loss per share have narrowed from $3.22 to $3.19 for 2025 in the past 60 days. The loss per share estimate for 2026 has narrowed from $3.19 to $2.51 in the same time frame. ETNB’s shares have risen 19% year to date.
89bio’s earnings beat estimates in two of the trailing four quarters and missed in the other two, delivering a negative average surprise of 37.49%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y
Perrigo Company plc (PRGO - Free Report) reported adjusted earnings of 93 cents per share in the fourth quarter of 2024, beating the Zacks Consensus Estimate of 92 cents. The reported figure increased 8% year over year, primarily due to improved margins and lower variable expenses.
Net sales declined 1.6% year over year to $1.14 billion, missing the Zacks Consensus Estimate of $1.20 billion. The downside was due to the loss of sales stemming from exited businesses and product lines.
During the quarter, sales dropped 2.1% year over year on account of exited businesses and product lines and another 0.1% from unfavorable currency movement. At constant currency (excluding foreign currency translation), sales fell 1.5%. Organic net sales (excluding the effects of acquisitions and divestitures and the impact of currency) rose 0.7%.
See the Zacks Earnings Calendar to stay ahead of market-making news.
Year to date, shares of Perrigo have lost 6.1% against the industry’s 11% growth.
Image Source: Zacks Investment Research
More on PRGO’s Earnings
Perrigo reports its results under the following segments — Consumer Self Care Americas (CSCA) and Consumer Self Care International (CSCI).
CSCA: The segment’s net sales in the quarter came in at $744 million, flat year over year. Though sales grew across the Nutrition, Skin Care and Women's Health categories, sales in the Pain & Sleep Aids, Upper Respiratory and Digestive Health categories offset this growth. Organic net sales rose 0.1%.
CSCI: The segment reported net sales of $394 million, down 4.5% from the year-ago period’s levels due to product line exits and unfavorable currency movements. At constant currency rates, sales were down 4.1% year over year. Organically, sales increased 1.8%.
Full-Year 2024 Results
Perrigo reported revenues of $4.37 billion, down 6.1% year over year. Net sales also fell 4.5% organically.
The company reported adjusted earnings of $2.57 per share for 2024, down 0.4% year over year.
PRGO’s 2025 Guidance
Perrigo will be hosting a virtual Investor Day today, where management will share the company’s 2025-2027 strategic plan to boost performance. During the event, management will also issue its financial guidance for the full year 2025.
PRGO’s Zacks Rank
Perrigo currently has a Zacks Rank #3 (Hold).
Perrigo Company plc Price
Perrigo Company plc price | Perrigo Company plc Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks are argenx (ARGX - Free Report) , Pacira BioSciences (PCRX - Free Report) and 89bio (ETNB - Free Report) . While ARGX and PCRX sport a Zacks Rank #1 (Strong Buy) each at present, ETNB carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for argenx’s 2025 earnings per share (EPS) have increased from $2.07 to $3.13 over the past 60 days, while the same for 2026 has increased from $9.08 to $10.85. ARGX’s shares have gained 2% year to date.
argenx's earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 339.37%.
Estimates for Pacira BioSciences’ 2025 EPS have increased from $3.16 to $3.20 over the past 60 days, and the same for 2026 has risen from $2.79 to $3.59. PCRX’s shares have surged 35% year to date.
Pacira’s earnings beat estimates in two of the trailing four quarters, missed once and met in the other, delivering an average surprise of 7.13%.
Estimates for 89bio’s loss per share have narrowed from $3.22 to $3.19 for 2025 in the past 60 days. The loss per share estimate for 2026 has narrowed from $3.19 to $2.51 in the same time frame. ETNB’s shares have risen 19% year to date.
89bio’s earnings beat estimates in two of the trailing four quarters and missed in the other two, delivering a negative average surprise of 37.49%.